Related Experiment Video
Updated: Jun 2, 2026
12:44
The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
Phase 1 clinical trials for sarcomas: the cutting edge
Vivek Subbiah1, Razelle Kurzrock
1Department of Investigational Cancer Therapeutics (A Phase I Program), University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA. vsubbiah@mdanderson.org
Current Opinion in Oncology
|April 27, 2011
Summary
Advanced sarcoma patients benefit from targeted drugs in early-phase trials. Identifying predictive biomarkers is key to translating research into clinical benefit for refractory sarcoma.
Area of Science:
- Oncology
- Translational Research
- Clinical Therapeutics
Background:
- Limited standard second-line treatments for advanced sarcoma.
- Early-phase clinical trials offer targeted and nontargeted agents.
- Developmental therapeutics are crucial for refractory cases.
Purpose of the Study:
- Review recent phase 1 clinical trials in sarcoma.
- Explore challenges in sarcoma developmental therapeutics.
- Highlight future opportunities for targeted therapies.
Main Methods:
- Review of published phase 1 clinical trials.
- Analysis of novel targeted and nontargeted agents.
- Exploration of combination therapies.
Main Results:
- Molecularly targeted agents show efficacy in sarcoma phase 1 trials.
- Examples include IGF1R antibodies, Apo2L/TRAIL agonists, crizotinib, cedarinib, and rexin-G.
- Combination chemotherapy with trabectedin demonstrates efficacy in soft tissue sarcoma.
Conclusions:
- Refractory sarcoma patients benefit from targeted drugs in phase 1 trials.
- Sarcomas with defined translocations or specific activated kinases are promising for targeted therapy.
- Biomarker identification for response/resistance is a primary challenge for clinical translation.
Related Concept Videos
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...